These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28819050)

  • 1. PDA PAC iAM 2017 Survey on Post Approval Change: Is the Regulatory Environment Hindering Much-Needed Innovation in the Pharma Industry?
    ; Ramnarine E; Busse U; Colao M; Edwards J; Follman K; Gale K; Good K; Kiani S; Jornitz M; Munk M; O'Donnel K; Seymour M; Simianu M; Skeens L; Vinther A; Baker D; Levy R
    PDA J Pharm Sci Technol; 2017; 71(5):421-427. PubMed ID: 28819050
    [No Abstract]   [Full Text] [Related]  

  • 2. Patents for second medical indications and their potential impact on pharmacare in Canada.
    Scassa T
    Health Law J; 2001; 9():23-59. PubMed ID: 12141223
    [No Abstract]   [Full Text] [Related]  

  • 3. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.
    Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK
    Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability.
    Vinther A; Ramnarine E; Gastineau T; O'Brien L; Brehm O; Fryrear D
    Ther Innov Regul Sci; 2024 May; 58(3):433-442. PubMed ID: 38369639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharma in-licensing 2007--cost versus paucity.
    Williams M
    Curr Opin Investig Drugs; 2007 Jan; 8(1):17-24. PubMed ID: 17263181
    [No Abstract]   [Full Text] [Related]  

  • 7. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 8. Bill 102: deal or no deal for big pharma.
    Rasky H
    Health Law Can; 2007 May; 27(4):73-84. PubMed ID: 17580795
    [No Abstract]   [Full Text] [Related]  

  • 9. Ensuring the safety of genotech drugs through implied warranty theory.
    Serra WM
    Am J Law Med; 1997; 23(2-3):363-81. PubMed ID: 9262761
    [No Abstract]   [Full Text] [Related]  

  • 10. Moving goalposts--regulatory oversight of antibacterial drugs.
    Brenner R; Ellis-Grosse EJ; Echols R
    Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 12. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A
    Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory watch: impact of PDUFA on regulatory decision-making.
    Hay M
    Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
    [No Abstract]   [Full Text] [Related]  

  • 14. Fast-track approval of medicines in Australia.
    Nash L
    Lancet Oncol; 2016 Nov; 17(11):1487. PubMed ID: 27693239
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The road ahead for large pharma: long-term science and innovation.
    Lundberg JM; Reilly C
    Drug Discov Today; 2009 May; 14(9-10):439-41. PubMed ID: 19429501
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 20. Walking the drug regulatory tightrope.
    Dove A
    Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.